www.innocyto.com

InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103
Irvine, CA 92618
Email: info@innocyto.com
Phone: 1-949-418-7543

Anti-human HLA-G Antibody

Catalog Number:	112601, 112602
Size:	25 ug, 100 ug
Target Name:	HLA-G, Human Leukocyte Antigen-G
Regulatory Status:	RUO

PRODUCT DETAILS

Clone:	HLAGAM1
Application:	Flow Cytometry
Reactivity:	Human
Format:	Purified
Isotype:	Mouse IgG1
Antibody Type:	Monoclonal
Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide
Protein Concentration:	0.5 mg/mL
Storage&Handling:	The antibody solution should be stored between 2°C and 8°C
Recommended Usage:	For flow cytometric staining, it is recommended to use less than 0.2 ug of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application
Isotype Control:	301401
GeneID:	3135
RRID:	AB_3758989

BACKGROUND INFORMATION

HLA-G is a non-classical major histocompatibility complex (MHC) class I molecule encoded within the human leukocyte antigen (HLA) region. Unlike classical MHC class I proteins, HLA-G has limited polymorphism and a restricted tissue distribution, primarily expressed at the maternal–fetal interface, where it plays a critical role in immune tolerance during pregnancy.

Structurally, HLA-G consists of a heavy chain associated with β2-microglobulin and presents peptides similarly to other MHC class I molecules. However, alternative splicing generates multiple isoforms, including both membrane-bound (e.g., HLA-G1) and soluble forms (e.g., HLA-G5). These structural variants contribute to its diverse immunomodulatory functions.

HLA-G interacts with inhibitory receptors such as ILT2 (LILRB1), ILT4 (LILRB2), and KIR2DL4 expressed on immune cells including natural killer (NK) cells, T cells, and antigen-presenting cells. Through these ligand–receptor interactions, HLA-G suppresses immune responses by inhibiting cytotoxic activity, reducing cytokine production, and promoting regulatory cell phenotypes.

In disease contexts, aberrant expression of HLA-G has been associated with cancer, viral infections, and autoimmune disorders.

Many tumors exploit HLA-G expression to evade immune surveillance, leading to poorer clinical outcomes. Conversely, reduced HLA-G expression may contribute to pregnancy complications such as preeclampsia or recurrent miscarriage.

Therapeutically, HLA-G represents a promising target in both immunosuppression and immuno-oncology. Enhancing HLA-G activity could be beneficial in transplantation and autoimmune diseases by promoting immune tolerance. In contrast, blocking HLA-G or its receptors is being explored as a strategy to restore anti-tumor immunity. Ongoing research aims to better understand its mechanisms and develop targeted therapies that modulate HLA-G pathways.

PRODUCT DATA



JEG-3 cells were stained with purified Anti-Human HLA-G clone HLAGAM1 (color-filled histogram) or an isotype control (right).

This product is supplied subject to the terms and conditions at www.innocyto.com/web/terms.php and may only be used as provided in the stated terms. Products are for Research Use Only.